UBS Maintains Buy on Perspective Therapeutics, Lowers Price Target to $7
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $18 to $7.
UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $18 to $7.